GAD2 and inclusion body myositis: Although autoantibodies against CN1A are known to be a biomarker for sporadic inclusion body myositis (IBM) and are widely detected in other autoimmune diseases (e.g. Sjögren’s syndrome, or systemic lupus erythematosus), none of the CN1A/GAD65 antibody-positive patients presented such syndrome.